Sufentanil alleviates pre-eclampsia via silencing microRNA-24-3p to target 11β-Hydroxysteroid dehydrogenase type 2.
11β-hydroxysteroid dehydrogenase type 2
HTR8/SVneo cells
Sufentanil
preeclampsia
trophoblast
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
6
5
2022
Statut:
ppublish
Résumé
Pre-eclampsia (PE) is a prevalent pregnancy disease characterized by insufficient trophoblast cell migration (HTR8/SVneo). Consequently, accelerating trophoblast cell proliferation might ameliorate PE. This study assessed the effects and molecular mechanisms of Sufentanil (SUF) on HTR8/SVneo cells proliferation. HTR8/SVneo cells and PE clinical samples were used. Peripheral blood was collected from PE patients' samples, and microRNA (miR)-24-3p and 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) was analyzed in the blood and cells. HTR8/SVneo cells were treated with varying SUF concentrations or transfected with miR-24-3p mimics/inhibitors, or HSD11B2 elevation vector. CCK-8, colony formation, transwell, and flow cytometry assays were then carried out. Association of miR-24 - 3p with HSD11B2 was investigated. PE animal model was constructed using Wistar rats to verify SUF's role on PE
Identifiants
pubmed: 35506414
doi: 10.1080/21655979.2022.2066753
pmc: PMC9275916
doi:
Substances chimiques
MIRN24 microRNA, human
0
MIRN24 microRNA, rat
0
MicroRNAs
0
Sufentanil
AFE2YW0IIZ
11-beta-Hydroxysteroid Dehydrogenase Type 2
EC 1.1.1.146
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11456-11470Références
Cell Cycle. 2021 Feb;20(4):383-391
pubmed: 33475463
Genome Res. 2009 Jan;19(1):92-105
pubmed: 18955434
Drug Des Devel Ther. 2021 May 18;15:2143-2149
pubmed: 34040352
Chin Med J (Engl). 2015 Jun 20;128(12):1627-35
pubmed: 26063365
Yonsei Med J. 2011 Jan;52(1):1-12
pubmed: 21155028
Biosci Biotechnol Biochem. 2021 Feb 18;85(2):280-286
pubmed: 33604643
Onco Targets Ther. 2020 Apr 15;13:3151-3163
pubmed: 32346298
Inflammation. 2021 Jun;44(3):1160-1174
pubmed: 33751357
J Am Coll Cardiol. 2020 Oct 6;76(14):1690-1702
pubmed: 33004135
Genet Test Mol Biomarkers. 2020 Jun;24(6):321-327
pubmed: 32511062
BMC Genet. 2014 Sep 09;15:96
pubmed: 25200528
Biosci Trends. 2019 Mar 14;13(1):49-57
pubmed: 30773504
J Pers Med. 2021 Jan 11;11(1):
pubmed: 33440716
Cell Mol Immunol. 2019 Jan;16(1):302-312
pubmed: 30487550
J Int Med Res. 2021 Feb;49(2):300060520986351
pubmed: 33535837
J Obstet Gynaecol. 2009 Feb;29(2):114-8
pubmed: 19274543
J Obstet Gynaecol. 2021 Aug;41(6):910-914
pubmed: 33228451
Thromb Res. 2016 Jan;137:126-140
pubmed: 26632513
J Cell Physiol. 2019 Feb;234(2):1052-1061
pubmed: 30256424
Expert Opin Pharmacother. 2020 Aug;21(12):1407-1418
pubmed: 32486875
Anesth Analg. 2003 Sep;97(3):867-872
pubmed: 12933418
Arch Biochem Biophys. 2018 Dec 1;659:13-21
pubmed: 30261165
Med Sci Monit. 2019 Mar 28;25:2265-2273
pubmed: 30918241
Clin Exp Hypertens. 2019;41(3):268-273
pubmed: 29750583
Pregnancy Hypertens. 2018 Jan;11:7-11
pubmed: 29523277
J Endocrinol. 2020 Jan;244(1):177-187
pubmed: 31600723
PLoS One. 2014 Sep 17;9(9):e107938
pubmed: 25229504
J Pharm Anal. 2019 Aug;9(4):217-226
pubmed: 31452959
Micromachines (Basel). 2021 Nov 17;12(11):
pubmed: 34832823